compounded semaglutide ruling How the FDA's Impacts Aesthetics Practices: Navigating Compliance and Weight Loss Programs The FDA's Decision to Ban

Draw the wrong amount and you have either doubled your dose or cut it in half

doi: 10.7150/thno.21945 49 WuFLiuJ

Retatrutide appears to have a similar safety profile to other GLP-1 medications: No increased risk of pancreatitis in trials so far No hepatotoxicity signals (liver damage) No cases of ketoacidosis Serious adverse events were rare (2.5% of participants) The trials are ongoing, so we'll learn more about long-term safety

Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) are at a higher risk of developing thyroid C-cell tumors

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Perics JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V